紫杉醇联合卡铂方案在三阴性乳腺癌辅助化疗中的临床应用效果

Clinical Effects of Paclitaxel and Carboplatin on the Adjuvant Chemotherapy of Triple Negative Breast Cancer

目的探究紫杉醇联合卡铂方案在三阴性乳腺癌辅助化疗中的临床应用效果。方法选取2020年6月至2022年6月河南大学第一附属医院收治的82例三阴性乳腺癌患者,采用随机数字表法将其分为参照组(环磷酰胺、表柔比星、紫杉醇治疗)和试验组(紫杉醇联合卡铂方案)各41例,对客观缓解率(ORR)、疾病控制率(DCR)、不良反应发生率、肿瘤标志物水平、免疫功能、生活质量进行分析比较。结果试验组ORR(60.00%)、DCR(88.00%)、均较参照组(20.00%、48.00%)高,差异有统计学意义(P<0.05)。试验组不良反应发生率(56.10%)显著低于参照组(95.12%),差异有统计学意义(P<0.05)。两组干预前肿瘤标志物差异无统计学意义(P>0.05),试验组干预后甲胎蛋白(AFP)、癌胚抗原(CEA)、糖抗原125(CA125)、鳞状上皮细胞癌抗原(SCC-Ag)均低于参照组,差异有统计学意义(P<0.05)。两组干预前免疫功能差异无统计学意义(P>0.05),试验组干预后的辅助性T细胞(CD4+)、CD4+/细胞毒性T细胞(CD8+)高于参照组,但CD8+低于参照组,差异有统计学意义(P<0.05)。两组干预前卡氏评分(KPS)比较,差异无统计学意义(P>0.05),干预后试验组评分高于参照组,差异有统计学意义(P<0.05)。结论将紫杉醇联合卡铂方案应用于三阴性乳腺癌辅助化疗中,可显著提升疗效,且患者对相关不良反应能够耐受,改善患者预后、肿瘤标志物,同时增强免疫能力,提升患者生活质量。

Objective To explore the clinical effects of paclitaxel and carboplatin on the adjuvant chemotherapy of triple negative breast cancer.Methods A total of 82 triple negative breast cancer patients admitted in the First Affiliated Hospital of Henan University from June 2020 to June 2022 were selected.According to random number table,patients were randomly divided into reference group(N=41,cyclophosphamide,pharmorubicin,paclitaxel)and trial group(N=41,paclitaxel and carboplatin).The objective response rate(ORR),disease control rate(DCR),prevalence of adverse reactions,tumor markers,immune function and quality of life were compared between the two groups.Results ORR and DCR in the trial group(60.00%,88.00%)were higher than reference group(20.00%,48.00%),with significant differences(P<0.05);The adverse reactions rate in the trial group(56.10%)was significantly lower than reference group(95.12%),with significant difference(P<0.05);Before intervention,the tumor markers between groups were not significantly different(P>0.05);After intervention,alpha fetoprotein(AFP),carcino-embryonic antigen(CEA),carbohydrate antigen 125(CA125)and squamous cell carcinoma antigen(SCC-Ag)levels in the trial group were significantly lower than reference group,with significant differencess(P<0.05);Before intervention,the immune function indicators between groups were not significantly different(P>0.05);After intervention,the helper T cell(CD4+)and CD4+/cytotoxic T cell(CD8+)values in the trial group were significantly higher than reference group,but CD8+values were lower than reference group,with significant differences(P<0.05);Before therapy,Karnofsky performance status(KPS)scores between groups were not significantly different(P>0.05);After therapy,KPS scores in the trial group were significantly higher than reference group,with significant differences(P<0.05).Conclusion The combination of paclitaxel and carboplatin in adjuvant chemotherapy for triple-negative breast cancer can significantly improve the efficacy,and patients can tolerate the related adverse reactions,improve the prognosis and tumor markers,and enhance the immune capacity,and improve the quality of life of patients.